The Devil Is In The Details – A Checklist For Developing Successful Eu Pharma And Medtech Forecasts

Forecasting the value of biopharmaceutical and MedTech assets often begins with the US market, given its size and significance. Successfully transitioning these forecasts to European markets, or beginning with a Europe-first strategy, requires careful consideration and expertise, often leading to a redefinition of forecast structures and assumptions.

Key Takeaways

• Key market differences: how variations in market landscapes, patient and prescriber attitudes and behaviors, regulation, and market access and pricing environments influence the structure and assumptions underlying EU forecasts
• Success factors: the most important elements that contribute to successful forecasting in European markets